E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Newly diagnosed acute myeloid leukaemia (AML) in patients ≥ 18 years of age |
|
E.1.1.1 | Medical condition in easily understood language |
Newly diagnosed acute myeloid leukaemia (AML) in patients ≥ 18 years of age |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10024291 |
E.1.2 | Term | Leukaemias acute myeloid |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To assess the safety and tolerability of HU at three different dose-levels added to standard AML therapy consisting of ara-C and daunorubicin (frequency and severity of toxicities; dose-finding)
1. To assess the effect of HU added to standard AML therapy consisting of ara-C and daunorubicin on the rate of negative minimal residual disease (MRD-negativity) after the second standard chemotherapy cycle |
|
E.2.2 | Secondary objectives of the trial |
1. To assess the time to haematopoietic recovery after each chemotherapy treatment cycle 2. To assess the effect of HU added to standard AML therapy consisting of ara-C and daunorubicin on ara-CTP accumulation in peripheral blasts 3. To assess the effect of HU added to standard AML therapy on remission (CR/CRi/MLFS) 4. To assess the effect of HU added to standard AML therapy on event-free survival (EFS) 5. To assess the effect of HU added to standard AML therapy on relapse-free survival (RFS) two years after diagnosis 6. To assess the effect of HU added to standard AML therapy on overall survival (OS) two years after diagnosis 7. To assess the role of SAMHD1 protein expression for secondary objectives 2-6
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients with: - a diagnosis of AML and related myeloid precursor neoplasia according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML, or - acute leukaemia of ambiguous lineage according to WHO 2008
• Patients 18 years and older.
• Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values: - Serum creatinine ≤ 220 μmol/L, unless considered AML-related - Serum bilirubin ≤ 2.5 x upper limit of normal (ULN, i.e. ≤65 µmol/L), unless considered AML-related or due to Gilbert’s syndrome - Alanine aminotransferase (ALAT) ≤ 2.5 x ULN, i.e. ≤ 1.9 µcat/L and ≤ 2.9 for females and males, respectively, unless considered AML-related
• Male patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
• Written informed consent.
• Patient is capable of giving informed consent.
|
|
E.4 | Principal exclusion criteria |
• Acute promyelocytic leukemia.
• CNS leukaemia
• Ongoing treatment with gemtuzumab-ozogamicin.
• Major organ failure precluding administration of planned chemotherapy.
• Glomerular filtration rate (GFR) < 30 ml/min
• Cardiac dysfunction as defined by: - Myocardial infarction within the last 3 months of study entry, or - Reduced left ventricular function with an ejection fraction < 40% as measured by echocardiogram (will only be performed when clinically suspected) or - Unstable angina or - New York Heart Association (NYHA) grade IV congestive heart failure (see Appendix I) or - Unstable cardiac arrhythmias
• Known intolerance to any of the chemotherapeutic drugs in the protocol.
• Positive pregnancy test. Lactating female or female of childbearing potential not using adequate contraception.
• Fanconi anaemia
• Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• MRD-negativity after cycle 2
Definition of MRD: malignant blasts as a percentage of total bone-marrow cells and as a percentage of the whole white blood cell compartment. These percentages are calculated based on the frequency of cells with an aberrant phenotype.
It is nowadays well established that minimal residual disease (MRD) can be a clinical surrogate marker for survival, in particular relapse-free survival. A recent study of the Belgian-Dutch study consortium HOVON that is actively collaborating with the Swedish AML group has reported retrospective analyses on the power of MRD of patients in clinical remission to predict relapse. MRD-positivity was defined as ≥ 0.1% leukemic cells in bone marrow samples. The frequency of MRD-positivity declines with the number of chemotherapy courses and is approximately 50%, 30% and 25% after course 1, 2, and 3, respectively. MRD is assessed as described in the standard of care by the Swedish AML group. For the purpose of the study, MRD will be assessed around four weeks after chemotherapy cycle 2. MRD is patient-specific, and will be performed by flow cytometry that follows a specific leukaemia-associated immunophenotype (LAIP) that is established at diagnosis using a panel of 8-10 cell surface markers. A threshold of MRD-positivity is defined by the presence of more than 0.1% leukemic blasts in the sample. If a mutation in NPM1 or core binding factor (CBF) fusion genes have been identified, PCR-based MRD-assessment standardised local routine will be performed instead of flow cytometry In patients for whom a LAIP is not available and that do not have mutations in NPM1 or CBF fusions, other genetic aberrations detected in the routine genetic testing of diagnostic AML samples can be used for validated (digital droplet) polymerase-chain reaction ((dd)PCR) or next-generation sequencing (NGS) based MRD diagnostics. If no MRD values were determined at the local treating centre, ddPCR or NGS-based MRD analyses will be performed retrospectively on biobanked samples. If biobanked material is not available, material will be requested from routine diagnostic samples. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Following treatment cycle 2 |
|
E.5.2 | Secondary end point(s) |
• Safety and tolerability (frequency and severity of non-hematological toxicities). • Time to hematopoietic recovery (ANC 0.5 and 1.0 x 109/L; platelets 50 x 109/L) after each chemotherapy treatment cycle, defined as the time from the start of the cycle until recovery. • Efficacy profile (response rate (CR, CRi, MLFS), event free survival (EFS), relapse-free survival (RFS), and overall survival (OS))
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
MRD-negativity after cycle 2
response rate (CR, CRi, MLFS, PR) after cycle 2
event free survival (EFS) and overall survival (OS) after the end of the trial
ara-CTP amounts after first and second ara-C infusion on day 1 of cycle 1
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Evaluation of safety when combined with standard-AML therapy |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |